About Company
Allogene Therapeutics is a clinical-stage biotechnology company focused on developing allogeneic CAR T cell therapies for the treatment of cancer.
Founded in 2018 and headquartered in South San Francisco, California, Allogene Therapeutics aims to revolutionize cancer treatment through its innovative AlloCAR T™ platform. The company specializes in creating "off-the-shelf" allogeneic T-cell therapies, which utilize T cells from healthy donors to provide scalable and accessible treatment options for patients with hematological malignancies and solid tumors. Allogene's pipeline includes several promising candidates, such as UCART19 and ALLO-501, targeting various cancer types. The company emphasizes collaboration in research and development, striving to enhance the effectiveness of immuno-oncology therapies.